■Abstract #LBA2　　

SEARCH試験: 肝細胞癌 (HCC) におけるSorafenib vs. Sorafenib + Erlotinib療法のプラセボ対照二重盲検無作為化比較第III相試験

SEARCH: A phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)

A.X. Zhu, et al.

■Abstract #LBA3

進行胃癌における1st-line治療としてのCapecitabine + Cisplatin (XP) 療法±Cetuximabの無作為化比較第III相試験 (EXPAND試験)

Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study

F. Lordick, et al.

■Abstract #LBA4　　

治癒切除後のstage III結腸癌患者における術後補助化学療法としてのFOLFOX4 ± Cetuximab療法: PETACC8 Intergroup第III相試験のDFSおよびOSの最新報告とサブグループ解析

Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 Intergroup Phase III Trial

J. Taieb, et al.

■Abstract #LBA17

Bevacizumabによる1st-line治療を受けた切除不能進行・再発大腸癌症例における、初回増悪後Bevacizumab継続投与の無作為化試験: BEBYP試験 (GONOグループ)

A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO).

G. Masi, et al.

■Abstract #LBA19

進行胃癌に対するS-1 vs. S-1 + Docetaxel療法の有用性を検討した無作為化比較第III相試験:START試験：2012年最新報告 (JACCROとKCSGの共同研究より)

S-1 plus Docetaxel versus S-1 for Advanced Gastric Cancer (START Trial) Update 2012 (JACCRO and KCSG study Group)

K. Yoshida, et al.

■Abstract #524PD

L-OHPベースの術前化学療法を実施したstage III結腸癌患者における生存に対する効果を予測するバイオマーカーとしてのERCC1およびMMR発現

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin based adjuvant chemotherapy

P. Li, et al.

■Abstract #526PD　　

Cetuximab併用化学療法を施行された切除不能進行・再発大腸癌患者におけるAmphiregulin (AREG) /Epiregulin (EREG) ならびにEGFR-FISH発現を用いた効果予測スコアの開発：AIO CRC-0104試験の解析

Development of a Predictive Score Using Amphiregulin (AREG), Epiregulin (EREG) and EGFR-FISH Expression Levels to Determine Treatment Efficacy in mCRC Patients Receiving Cetuximab-based Therapy. -Analysis of the German AIO CRC-0104 Trial

V. Heinemann, et al.

■Abstract #558P　　

KRAS 野生型切除不能進行・再発大腸癌におけるPanitumumab + FOLFOX療法の奏効および早期腫瘍縮小の意義に関する見解 (PRIME試験より)

Understanding the Value of Response and Early Tumour Shrinkage in Patients with Wild-Type KRAS Metastatic Colorectal Cancer Treated with Panitumumab plus FOLFOX

J.-Y. Douillard, et al.

■Abstract #564P　　

KRAS 野生型の切除不能進行・再発大腸癌1st-line治療におけるPanitumumab + FOLFOX療法 vs. FOLFOX療法の生存に関する質的調整解析 (PRIME試験より)

Quality-Adjusted Survival in Patients with Wild-type (WT) KRAS Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy with Panitumumab plus FOLFOX versus FOLFOX alone

J. Wang, et al.

■Abstract #570P　　

Panitumumab + 化学療法併用療法を受けたKRAS 野生型切除不能進行・再発大腸癌患者に対するプロトコール治療後の抗EGFR抗体薬使用が生存率に及ぼす影響

Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy on Survival Outcomes in Patients with Wild-Type KRAS Metastatic Colorectal Cancer Treated with Panitumumab plus Chemotherapy

J.-Y. Douillard, et al.

■Abstract #572P

PANERB STUDY: Cetuximabベース化学療法後に増悪した切除不能進行・再発大腸癌に対するPanitumumabによる治療でベネフィットを得られる症例とは？

PANERB STUDY: Which category of patients, suffering from metastatic colorectal cancer (mCRC), can benefit from panitumumab treatment after cetuximab-based regimen failure?

J.-P. Metges, et al.

■Abstract #587P　

日本人治癒切除不能大腸癌患者におけるPanitumumabの製造販売後調査：中間報告(3,005例)

Post-marketing survey of panitumumab in Japanese patients with unresectable colorectal cancer: Interim report of 3,005 patients

K. Sugihara, et al.

■Abstract #605P　　

大腸癌肝転移患者における1st-line治療としての Panitumumab + L-OHP + Capecitabine併用療法の第�U相試験: METAPAN試験

Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: THE METAPAN Study

F. Leone, et al.